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Background: Hypericum japonicum Thunb. ex Murray is widely used as an herbal medicine for the treatment of
hepatitis and tumours in China. However, the molecular mechanisms of its effects are unclear. Our previous
research showed that extracts of H. japonicum can induce apoptosis in leukaemia cells. We also previously
systematically analysed and isolated the chemical composition of H. japonicum.
Methods: The fluorescence polarisation experiment was used to screen for inhibitors of Bcl-2 proteins which are
proved as key proteins in apoptosis. The binding mode was modelled by molecular docking. We investigated the
proliferation attenuating and apoptosis inducing effects of active compound on cancer cells by MTT assay and
flow cytometry analysis. Activation of caspases were tested by Western blot. A broad-spectrum caspase inhibitor
Z-VAD-FMK was used to investigate the caspases-dependence. In addition, co-immunoprecipitation was
performed to analyse the inhibition of heterodimerization between anti-apoptotic Bcl-2 proteins with
pro-apoptotic proteins. Moreover, in vivo activity was tested in a mouse xenograph tumour model.
Result: Jacarelhyperol A (Jac-A), a characteristic constituent of H. japonicum, was identified as a potential Bcl-2
inhibitor. Jac-A showed binding affinities to Bcl-xL, Bcl-2, and Mcl-1 with Ki values of 0.46 μM, 0.43 μM, and 1.69
μM, respectively. This is consistent with computational modelling results, which show that Jac-A presents a
favorable binding mode with Bcl-xL in the BH3-binding pocket. In addition, Jac-A showed potential growth inhibitory
activity in leukaemia cells with IC50 values from 1.52 to 6.92 μM and significantly induced apoptosis of K562 cells by
promoting release of cytochrome c and activating the caspases. Jac-A also been proved that its effect is partly
caspases-dependent and can disrupt the heterodimerization between anti-apoptotic Bcl-2 proteins with pro-apoptotic
proteins. Moreover, Jac-A dose-dependently inhibited human K562 cell growth in a mouse xenograph tumour model
with low toxicity.
Conclusion: In this study, a characteristic constituent of H. japonicum, Jac-A, was shown to induce apoptosis in leukaemia
cells by mediating the Bcl-2 proteins. Therefore, we propose a new lead compound for cancer therapy with a low toxicity,
and have provided evidence for using H. japonicum as an anti-cancer herb.
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The entire Hypericum japonicum herb, named “Tianji-
huang,” is widely used for the treatment of infectious
hepatitis, acute and chronic hepatitis, and tumour in
China [1]. An 85% ethanol-treated water extract is docu-
mented in the Chinese Pharmacopoeia as an injection
for the treatment of viral hepatitis [2,3]. Moreover,
H. japonicum is used as an animal feed in China because
of its widespread growth. These records demonstrate the
clinical safety of H. japonicum. However, the molecular
mechanisms of its effects are unclear. To better understand
the mechanisms of H. japonicum, its chemical composition
was systematically isolated and analysed in our previous
study. In this study, we identified jacarelhyperol A (Jac-A),
a characteristic constituent of H. japonicum, as a potent in-
hibitor of Bcl-2 proteins via high throughput screening of
an in-house natural product library (NPL).
The Bcl-2 family of proteins play an important role in
apoptosis through the balance of antiapoptotic proteins
(e.g., Bcl-2, Bcl-xL, Mcl-1) and proapoptotic proteins (e.g.,
Bak, Bax, Bad, Bid) [4]. The ability of antiapoptotic pro-
teins to form heterodimers with a number of proapoptotic
proteins is believed to play a crucial role in their antiapop-
totic function [5]. Antiapoptotic Bcl-2 proteins are overex-
pressed in a variety of tumours, which can protect cancer
cells from apoptosis [6,7]. Owing to their important func-
tions in regulating cell death, the pharmacological inhib-
ition of Bcl-2 proteins is a promising strategy for apoptosis
induction or sensitisation to chemotherapy [8]. Protein se-
quence analysis and structure-function studies revealed that
the BH3 domain of proapoptotic proteins is the fundamen-
tal motif for the dimerisation with antiapoptotic proteins
[9]. The three-dimensional structure of a complex of Bcl-xL
and the Bak BH3 domain peptide showed that the Bak pep-
tide is an amphipathic α-helix that binds to a hydrophobic
groove on the surface of Bcl-xL [10]. Based on these studies,
screening new ligands that bind to the same pocket became
an anti-cancer drug discovery strategy to search for antia-
poptotic protein inhibitors [11]. To screen for Bcl-2 protein
inhibitors, we used fluorescence polarisation (FP), whose
basic principle is that a fluorescent peptide tracer (Flu-Bid-
BH3) and a nonfluorescent small molecule inhibitor com-
pete for binding to the Bid BH3 domain of Bcl-2 proteins.
Jac-A was chosen as the candidate compound for further
research because of its high affinity with Bcl-2 proteins and
favorable binding mode with Bcl-xL. Then, we tested its
anti-cancer activity in vitro and in vivo. Jac-A possesses a
broad antitumour effect for all tested cancer cells and re-
markably inhibited the proliferation of leukaemia cells.
Moreover, Jac-A not only induced K562 cell apoptosis
in vitro, but also inhibited human K562 cell growth in a
mouse xenograph tumour model, which provided evidence
for using H. japonicum as an anti-cancer herbal medicine.
We also proved that Jac-A’s effect is partly caspase-dependent and it can disrupt the heterodimerization
between anti-apoptotic Bcl-2 family members with pro-
apoptotic Bcl-2 family members.
Methods
Fluorescence polarisation assay
The Bid BH3 domain peptide (sequence: EDIIRNIARH-
LAQVGDSMDR) was synthesised and labelled with 5-
Carboxyfluorescein (5-FAM) at the N-terminus. For the
competitive binding assay, 200 nM Bcl-xL, Bcl-2, or
Mcl-1 was mixed with various concentrations of com-
pounds in PBS (4.3 mM Na2HPO4, 1.4 mM KH2PO4,
137 mM NaCl, 2.7 mM KCl, pH 7.4). After incubation
for 1 h at 37°C, an equal volume of 200 nM 5-FAM-
labelled BH3 peptide was added to the solution. After
incubation for 10 min at 37°C, the fluorescence polarisa-
tion was measured on a TECAN Genios Pro microplate
reader. The excitation wavelength and emission wave-
length were set to 485 nm and 535 nm, respectively. The
50% inhibiting concentration (IC50) value was analysed
by the GraphPad Prism program. The Ki was calculated
by a web-based tool [12].
Molecular modelling
The refined structure of Bcl-xL (PDB: 2YXJ) was used
for prediction binding mode between Jac-A with Bcl-xL.
The program Maestro 9.0 was used for this assessment.
All water molecules were removed from the structure of
the complex. Hydrogen atoms and charges were added
during a brief relaxation that was performed using the
“Protein Preparation Wizard” workflow in Maestro 9.0.
After optimising the hydrogen bond network, the crystal
structure was minimised using the OPLS 2005 force field
with the maximum root mean square deviation (RMSD)
value of 0.3 Å. The grid-enclosing box was centred on
the ligand ABT-737 in the refined crystal structure as
described above, and defined so as to enclose the resi-
dues located within 14 Å from the ligand. This domain
has been identified as the BH3 domain, which is the fun-
damental motif for dimerization with the BH3 peptide.
The three-dimensional structure of Jac-A was generated
with the Ligprep module. Docking process was per-
formed using GLIDE with default docking parameter
setting with extra precision (XP) approach.
Cell culture
Cell lines MBA-MB-231, T47D, LOVO, A549, HepG2,
K562, HL-60, and THP-1 cells were obtained from the
American Type Culture Collection (Manassas, VA). All
cell culture supplies were obtained from Invitrogen
(Carlsbad, CA). Thiazolyl blue tetrazolium bromide
(catalogue no. M5655) and dimethyl sulfoxide (catalogue
no. D5879) were purchased from Sigma-Aldrich (St. Louis,
MO). Cells were cultured in RPMI 1640 (A549, K562,
Zhang et al. BMC Cancer 2014, 14:689 Page 3 of 11
http://www.biomedcentral.com/1471-2407/14/689THP-1), IMDM (HL-60), or DMEM (MBA-MB-231,
LOVO, T47D, HepG2) and maintained in a Thermo incu-
bator (Waltham, MA) with humidified air containing 5%
CO2 at 37°C. All culture media contained 10% FBS and
1% penicillin-streptomycin.
Cytotoxicity assay
The cytotoxic activitiy of Jac-A against human cancer
cells was measured by the MTT colorimetric assay. Four
thousand cells (per well) were seeded in 96-well plates
and treated with the compounds for 48 h at serial con-
centrations. Then, 10 μL MTT solution (5 mg/mL in
PBS) was added to each well, and the plates were incu-
bated for an additional 2–4 h at 37°C. The supernatant
was carefully removed, and 100 μL DMSO was added to
dissolve the formazan crystals. The absorbance at
570 nm was recorded on a BioTek Synergy 2 plate
reader (BioTek Instruments, Inc., Winooski, Vt, USA).
Detection of apoptosis by flow cytometry using Annexin
V-PI staining
After treated with 0 (control), 0.1, 1, 5, 10 μM/L Jac-A and
0.5% DMSO for 48 h, K562 cells from each group were
collected and diluted to a concentration of 1.0 × 106 per
mL. The cells were washed with cold PBS twice and resus-
pended in 100 μL Annexin-V-FITC (Sigma) diluted 1:100
in binding buffer (10 mM Hepes 100 mM NaCl, 10 mM
KCl, 1 mM MgCl2, 1.8 mM CaCl2) containing 10% propi-
dium iodide (PI, Sigma) for 30 min at 4°C. The apoptosis
were detected by Flow Cytometry (BD Biosciences).
Cytochrome c release assay
The method of preparing mitochondria and cytosol was
referenced to others [13-15]. Briefly, after treated with 0
(control), 3, 6, 12 μM/L Jac-A for 48 h, K562 cells (1 ×
106) were collected and washed once with ice-cold PBS
and re-suspended in mitochondrial isolation buffer
(250 mM sucrose, 20 mM HEPES, pH 7.4, 5 mM MgCl2
and 10 mM KCl ) containing 0.05% digitonin. Cells were
left on ice for 10 min followed by centrifugation at 13000
r.p.m. for 3 min. The pellete was the mitochondrial mem-
brane (heavy membrane proteins) portion. Soluble fraction
proteins and an equivalent amount of heavy membrane
proteins were subjected to SDS-PAGE and analysed by
Western blot with antibodies against Cyt c (Abcam, CA).
Caspase activation assay by western blotting
After treated with 0 (control), 3, 6, 12 μM/L Jac-A for
48 h, K562 cells (1 × 106) were collected and suspended
in lysis buffer containing 150 mM NaCl, 50 mM Tris
(pH 8.0), 0.02% NaN3, 0.01% PMSF, 0.2% Aprotinin, and
1% TritonX-100 supplemented with protease inhibitor
cocktail (Thermo Scientific). Fifty micrograms protein per
lane was electrophoresed on 10% SDS polyacrylamide gels.Nonspecific reactivity was blocked by 5% non-fat milk
prepared in TBST (10 mM Tris, 150 mM NaCl, 0.05%
Tween-20, pH 7.5) at room temperature for 1 h. The
membranes were incubated with antibodies diluted ac-
cording to the manufacturers’ instructions. Images were
captured by the Odyssey infrared imaging system (Li-Cor
Bioscience, Lincoln, NE). Protein densitometry was per-
formed with the Quantity One imaging software (Bio-Rad)
and normalised against β-actin. Antibodies for cleaved
PARP, PARP, cleaved caspase-9, caspase-9, cleaved
caspase-3, caspase-3, and β-actin were obtained from Cell
Signaling Technology (Beverly, MA).
Co-immunoprecipitation
Immunoprecipitation was prepared as the method re-
ported by others [14,16]. After treated with 0 (control), 3,
6, 12 μM/L Jac-A for 48 h, K562 cells (1 × 106) were col-
lected and suspended in CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]- 1-propansulfonate) lysis buffer con-
taining 150 mM NaCl, 10 mM HEPES [pH 7.4], 1%
CHAPS, 1 mM PMSF, 5 μg/ml leupeptin, 5 μg/ml aprotin
and 1 μg/ml pepstain A. 150 μg of K562 cell lysates in
500 μL of CHAPS lysis buffer were precleared for 60 min
at 4°C with 20 μL of a 1:1 slurry of protein A/G Plus-
Agarose (Santa Cruz Biotechnology, Cat.# sc 2003) and
1 μg of rabbit IgG. After a brief centrifugation (3000 × g
for 5 min at 4°C) to remove precleared beads, 1 μg of
rabbit anti-Bax or Bakpolyclonal antibody and 20 μL of
Protein G Plus-Agarose were added to the lysate, followed
by incubation at 4°C overnight on a rotating device, pre-
cipitates were washed four times with CHAPS buffer, re-
suspended in 30 μL 1× SDS electrophoresis sample
buffer (50 mM Tris–HCl (pH 6.8), 100 mM dithiothrei-
tol, 2% SDS, 0.1% bromophenol blue, and 10% glycerol),
electrophoresed, and analysed by Western blotting with
monoclonal antibodies against Bcl-xL, Bcl-2, Mcl-1,
Bax, and Bak, respectively. All antibodies in this experi-
ment were purchased from Abcam (Shanghai, CA)
Xenograph tumor model in mice
Female Balb/c nude mice (5 weeks old) were purchased
from Shanghai SLAC Laboratory Animal Co., LTD
(Shanghai, China). 5 × 106 K562 cells were subcutaneously
injected in the right flank of mice. When the tumours
reached approximately 200 mm3, the mice were randomly
divided into four groups (n = 10 mice/each group) and
treated with Jac-A at 2, 10, 50 mg/kg or vehicle by oral
gavage. Tumour growth was monitored by measuring the
tumour size twice a week for 3 weeks after treatment. A
digital calliper was used to measure the tumour in two or-
thogonal dimensions. The volume was calculated with the
formula (long dimension) × (short dimension)2/2. The
body weight and survival of the nude mice were moni-
tored throughout the experiments. All animal experiments
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ond Military Medical University in accordance with insti-
tutional and Chinese government guidelines for animal
experiments.Statistical analysis
The data from the in vitro and in vivo experiments at dif-
ferent time points for the different treatment groups were
analysed for statistical significance with the GraphPad
Prism program (GraphPad, San Diego, CA). One-way
ANOVA was used among groups, followed by the Mann–
Whitney U test for post hoc comparisons to determine
the P values. The statistical significance of differences in
the survival of mice from the different groups was deter-
mined by the log-rank test using the same program.Chemistry
The purity of Jac-A was verified with NMR and HPLC,
and the purity of Jac-A was 97%. Jacarelhyperol A [17],
isolated from Hypericum japonicum Thunb.ex Murray;
yellow powder; 1H-NMR (DMSO-d6, 500 MHz, δH): 6.78
(1H, d, J = 10 Hz), 5.86 (1H, d, J = 10 Hz), 7.63 (1H, d, J =
8 Hz), 7.03 (1H, d, J = 8 Hz), 7.51 (1H, d, J = 8 Hz), 6.92
(1H, d, J = 8 Hz), 6.29 (1H, s); 13C-NMR (DMSO-d6,
125 MHz, δC): 70.2, 71.0, 78.4 (×2), 79.2, 97.6, 98.6, 100.7
(×2), 101.4, 102.6, 102.9, 112.8, 113.0, 113.7 (×4), 115.7,
116.8, 128.2 (×2), 131.6, 132.7, 145.4, 145.9, 149.6, 151.0
(×2), 151.9, 159.8, 162.3, 162.8, 179.7 (×2), 179.9; ESIMS:
m/z 667 [M −H]−; (−)-Gossypol (98% purity) was pur-
chased from Sigma–Aldrich (Shanghai, CA)Figure 1 The inhibitory activity of Jac A to Bcl-2 proteins. (A) The stru
and Mcl-1 by fuoresence polarization. The substrate for the assay was a 5-F
EDIIRNIARHLAQVGDSMDR).Results
Screening active compounds
Fuoresence polarization was used to screen for Bcl-2
protein inhibitors. Jac-A was chosen as the candidate
compound for further research because of its high affinity
to Bcl-2 proteins. As shown in Figure 1 and Table 1, Jac-A
can dose-dependently bind to Bcl-xL, Bcl-2, and Mcl-1
with a Ki value of 0.46 μM, 0.43 μM, and 1.69 μM, respect-
ively, which near to the activity of positive control
(−)-Gossypol, a known Bcl-2 protein inhibitor.
Predicting the binding modes of Jac-A with Bcl-xL
To map the binding site of Jac-A, we built complex struc-
ture of the compound with Bcl-xL by docking (Figure 2).
Jac-A contains two xanthones and can generates many
conformations by rotating the C10 −O and O −C3″
bonds. The best binding model is shown in Figure 2A, in
which the two xanthones of Jac-A exhibit two different
orientations with a 90° dihedral angle and occupy three
sub-pockets (P2, P4, and P5). The three sub-pockets play
an important role in binding with pro-death BH3-only
proteins and ligands. The P2 pocket, formed by residues
Tyr-101, Ala-104, Leu-108, Val-126, Asn-135, Ala-142,
and Ser-145, makes hydrophobic contacts with the aro-
matic H ring of Jac-A. In the P4 pocket, the aromatic B
ring, double bond of the A ring, and the two methyl
groups at C-3 make hydrophobic contacts with the hydro-
phobic pocket formed by residues Glu-96, Phe-97, Gly-
138, and Tyr-195. Moreover, the hydrophobic group D
ring and isopropyl at C-2″ of Jac-A can generate a hydro-
phobic interaction with the P5 pocket formed by residues
Leu-130, Arg-132, and Arg-139. In addition, the threecture of Jac A. (B) The inhibitory curves of Jac-A to Bcl-xL, Bcl-2,
AM-labeled Bid BH3 domain peptide (amino sequence:
Table 1 Binding affinity of Jac-A and (−)-gossypol with
Bcl-xL, Bcl-2 or Mcl-1 determined by a fluorescence
polarisation assay (Ki, μM)
Compound Bcl-xL Bcl-2 Mcl-1
Jac-A 0.46 0.43 1.69
(−)-Gossypol 1.01 0.95 0.86
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bond with the polar atoms of residues Gly-138, Tyr-101,
and Glu-129 (Figure 2B).
Anti-cancer activity of Jac-A
Bcl-xL, Bcl-2, and Mcl-1 are overexpressed in multiple
cancer cells and contribute to tumour drug resistance
[18]. Since Jac-A binds to Bcl-xL, Bcl-2, and Mcl-1 with
high affinity and inhibits their interactions with the BH3
domain of proapoptotic proteins, we elected to study the
effect of Jac-A on cancer cells. Using the MTT assay, we
tested the cytotoxicity of Jac-A against various human
cancer cell lines. Remarkably, Jac-A induced a dose-
dependent reduction in cell viability compared to positive
control doxorubicin (Table 2). Jac-A exhibited cytotoxic
potency against breast cancer cells (MBA-MB-231, T47D),
colon cancer cells (LOVO), lung cancer cells (A549), liverFigure 2 The predicted binding mode of Jac-A in the binding site of
in the hydrophobic groove of Bcl-xL. Jac-A occupies three key sub-pockets
pro-death BH3-only proteins and ligands. The protein is rendered in green,
pockets are labelled with dash circles. (B) The interaction model between J
atoms of residues Gly-138, Tyr-101, and Glu-129. Bcl-xL is rendered as a cart
rendered as sticks. The residues are rendered in green, and the compound
black lines.cancer cells (HepG2), and leukaemia cancer cells (K562,
HL-60, THP-1). Jac-A showed strongest activity against
leukaemia cells with IC50 values from 6.52 to 9.92 μM.
Our results demonstrate that Jac-A possesses broad anti-
cancer effects.
In the next experiment, we tried to elucidate whether
the cytotoxicity caused by Jac-A is from apoptosis. K562
cells were treated with different concentrations of Jac-A
and the cytotoxic effects were evaluated by Annexin V
and PI dual staining [19]. Annexin V/PI staining in the
control group showed a large viable cell population
(marked as PI −AV−) and a small amount of early apop-
totic (PI −AV+), late apoptotic (PI + AV+), and dead
cells (PI + AV−). Jac-A resulted in a shift from viable
cells to early and late apoptotic cell population with little
change in the dead cell population, especially at the con-
centration of 10 μM. As shown in Figure 3, flow cytome-
try analysis showed that Jac-A induced K562 cell
apoptosis in a dose-dependent manner. Approximately
2.3% ± 0.9%, 9.5% ± 1.2%, 14.4% ± 2.3%, and 44.7% ± 3.3%
PI + AV + cell populations and 1.1% ± 0.7%, 10.2% ± 1.4%,
23.5% ± 3.1%, and 22.1% ± 2.3% PI-AV + cell populations
were detected in the 0.1, 1, 5, and 10 μM Jac-A groups,
respectively. While no significant apoptotic population
was detected in the control group or DMSO group.Bcl-xL (PDB code 2YXJ). (A) The binding site and orientation of Jac-A
(P2, P4, and P5) which play an important role in binding with
while the compound is rendered in purple. The P2, P4, and P5 binding
ac-A with Bcl-xL. Jac-A can form three hydrogen bonds with the polar
oon, while the residues in contact with the ligand and compound are
is coloured in purple. The hydrogen bonds are represented by dotted
Table 2 The inhibitory activity of Jac-A on tumour cells via MTT Assay (IC50, μM, n = 4, mean ± SD)
Compound Breast cancer Colon cancer Lung cancer Liver cancer Leukaemia
MBA-MB-231 T47D LOVO A549 HepG2 K562 HL-60 THP-1
Jac-A 22.61 ± 1.2 12.53 ± 1.6 33.24 ± 2.1 18.8 ± 1.6 10.71 ± 1.4 6.52 ± 0.36 9.01 ± 0.47 9.92 ± 0.95
Doxorubicina 0.13 ± 0.01 0.25 ± 0.02 0.24 ± 0.01 0.11 ± 0.01 0.34 ± 0.02 0.55 ± 0.03 0.68 ± 0.02 0.52 ± 0.03
aPositive control.
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apoptosis cells in the Jac-A-treated groups compared
with the control group. At the same conditions, the
positive control (−)-Gossypol showed similar activity of
induction apoptosis for K562 cells (Additional file 1:
Figure S1). Moreover, Jac-A presented similar activity of
apoptosis induction for other leukemia cells HL-60,
THP-1 and colon cancer cells LOVO (Additional file 1:
Figure S2-S4). After treated with 10 μM of Jac-A, 33.7% ±
3.1% PI + AV + and 29.2% ± 1.4% PI-AV + cell populations
were detected in HL-60 cells, and 35.1% ± 2.4% PI + AV +
and 27.8% ± 2.1% PI-AV + cell populations were detected in
THP-1 cells. However, the activity of apoptosis inductionFigure 3 Jac-A caused K562 cell apoptosis. 106 of K562 cells were treate
stained with Annexin V-FITC and propidium iodide, and analysed using flow c
population (PI − AV−), early apoptosis (PI − AV+), late apoptosis (PI + AV+) and
(B), or 0.1, 1, 5, 10 μM/L Jac-A (C, D, E and F). The results are one representatfor LOVO cells weaker than for leukaemia cells. Only
17.2% ± 1.6% PI +AV+ and 7.89% ± 2.2% PI-AV + cell pop-
ulations were detected in LOVO cells.
Jac-A activates caspases cascades
In the intrinsic apoptotic pathway, Bax and Bak, which are
regulated by anti-apoptotic Bcl-2 proteins and BH3-only
proteins, stimulate the release of cytochrome c from the
mitochondrial intermembrane space into the cytosol.
Then, cytochrome c induces apoptosome formation, with
the activation of caspase-9 as the apical caspase [20].
Caspase-9 further activates the effector caspase-3, which
cleaves several hundred cellular proteins, resulting in thed with different concentrations of Jac-A for 48 h. Cells were then
ytometry. Four different cell populations marked as the following: live cell
dead cells (PI + AV−). Cells were treated with no Jac-A (A), 0.5% DMSO
ive of three independent experiments.
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associated with apoptosis, including chromatin conden-
sation, nuclear fragmentation, and externalisation of
phosphatidylserine [21]. To elucidate whether cyto-
chrome c fits in Jac-A-induced apoptosis, Jac-A treated
K562 cells were lyzed, the cytosol and the mitochondrial
membrane portion of the treated cells were obtained
through a serial of ultra-centrifugation to probe cyto-
chrome c in both portions using Western blot analysis.
As shown in Figure 4A, release of cytochrome c into
cytosol was detected in a dose-dependent manner fromFigure 4 Jac-A induced caspase-dependent apoptosis in K562 cells. (A
cells were treated with different concentration of Jac-A for 48 h. Cytosol and m
to immunoblot with anti-Cyt c specific antibodie as described in Materials and
experiments. (B)Western blot showing conspicuous cleavage of caspase-3, ca
to protein extract preparation after treated with 0 (control), 3, 6, 12 μM/L
Western blot using anti-PARP, PARP, cleaved caspase-9, caspase-9, cleaved
of three independent experiments. (C) Jac-A-induced apoptosis was inhib
cells were first treated with or without different concentrations of Z-VAD-low as 3 μM of Jac-A at 48 h of treatment. Moreover, we
checked the cleavage of caspase-9, caspase-3, and PARP
by immunoblotting. As shown in Figure 4B, cleavages of
caspase-9, caspase-3, and PARP were detected after
K562 cells were treated with Jac-A for 48 h, which is
consistent with the previous observation that some in-
hibitors of antiapoptosis proteins can induce the activa-
tion of caspases [22,23]. In addition, to investigate
whether caspases play roles in Jac-A-induced apoptosis
of K562 cells, we did another apoptosis assay to
examine the effects of a broad-spectrum caspase inhibitor,) Cyt c release in Jac-A-induced apoptosis of K562 cells. 106 of K562
itochondrial heavy membrane samples were prepared and subjected
methods. The results are one representative of three independent
spase-9, and PARP in K562 cells treated with Jac-A. K562 cells subjected
Jac-A for 48 h. Then, fifty micrograms extracted protein subjected to
caspase-3, caspase-3, and β-actin. The results are one representative
ited in a concentration dependent manner by the Z-VAD-fmk. K562
fmk for 4 h, followed by the treatment of Jac-A (10 μM) for 48 h.
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K562 cells were first treated with or without different
concentrations of Z-VAD-fmk for 4 h, followed by the
treatment of Jac-A (10 μM) for 48 h. Cells undergoing
apoptosis were measured using by phosphatidylserine (PS)
externalization using AnnexinV/FITC in the presence of
propidium iodide (PI). As exhibited in Figure 4C, Jac-A-
induced apoptosis was inhibited in a concentration
dependent manner by the Z-VAD-FMK. These findings
suggest that Jac-A-induced apoptosis in K562 cells is
partly caspase-dependent.
Inhibition of the heterodimerization of antiapoptotic
proteins with pro-apoptotic proteins
To confirm that Jac-A binds to anti-apoptotic Bcl-2
family members and competes with binding of pro-
apoptotic proteins, co-immunoprecipitation was per-
formed to analyse if these interactions are disrupted by
Jac-A. As illustrated in Figure 5, 6 μM of Jac-A treat-
ment started to clearly inhibit the binding of Bcl-xL and
Bax. Exposed to 12 μM of Jac-A treatment, little Bcl-xL
was seen to bind to Bax. Similarly, less Bcl-2 was ob-
served to bind to Bax at 12 μM of Jac-A treatment than
other doses of Jac-A and vehicle control treatment.
Moreover, Jac-A also inhibited the binding of Mcl-1 to
Bak but the inhibitory effect was presented at 12 μM of
Jac-A treatment. These observations demonstrate that
Jac-A-induced apoptosis of K562 cells is involved inFigure 5 Jac-A inhibited the heterodimerization of
antiapoptotic proteins with pro-apoptotic proteins. Jac-A
inhibited the binding between Bax with Bcl-xL or Bcl-2 (A) and Bak
with Mcl-1 (B). K562 cells were treated with indicated concentrations
of Jac-A for 48 h. 150 μg of K562 cell lysates were subjected to
co-immunoprecipitation using anti-Bax and anti-Bak antibodies,
respectively, further immunoblot with anti- Bcl-xL, Bcl-2, Mcl-1, Bax,
or Bak antibody, as described in Materials and methods. The results
are one representative of three independent experiments.inhibiting the heterodimerization of antiapoptotic pro-
teins (Bcl-xL, Bcl-2, and Mcl-1) with pro-apoptotic pro-
teins (Bax, Bak).
Inhibitory effect of Jac-A on K562 cell growth in
xenograft mice
To test if Jac-A can inhibit K562 tumour cell growth
in vivo, we used nude mice that were injected s.c. with
K562 cells into the right flank. The K562-bearing mice
were randomly divided into four groups (ten mice in
each group) and treated with vehicle and Jac-A at a
dose of 2, 10, or 50 mg/kg daily for 21 days. As shown
in Figure 6A–C, Jac-A dose-dependently inhibited
tumor growth. Higher doses of Jac-A had a better
inhibitory effect and longer observed survival time
(Figure 6D). Interestingly, the body weight of the con-
trol group and mice treated with the low-dose of Jac-A
were significantly lower than mice from higher
dose groups (10 and 50 mg/kg) (Figure 6E). This
phenomenon can be attributed to the low toxicity and
therapeutic effect of Jac-A. In the process of this ex-
periment, the tumors’ growths of mice from higher
dose groups were significantly inhibited and the quality
of life better than control group and low-dose group.
The absorbed energy from food mainly used for keep-
ing the growth of tumor for mice in control group and
low-dose group, which contribute to losing weight.
However, this phenomenon improved in higher dose
groups. This finding suggests that Jac-A can effectively
inhibit the growth of tumor in vivo with low toxicity.
Discussion
Many anti-cancer drugs have significant side effects,
and some cancers are drug resistant [24-26]. There-
fore, potential anti-cancer compounds are needed in
pharmaceutical development. Natural products, with
inherently larger-scale structural diversity than syn-
thetic compounds, are the major resources of bioactive
agents and will continue to provide the most candi-
dates for new drug discovery. Many natural product
resources have been used as medicine, such as those in
traditional Chinese medicine. Active compounds from
medicinal plants are generally biologically friendly,
because of their clinical use. Here, we identified a new
natural Bcl-2 inhibitor Jac-A with potential therapeutic
use in murine models of human leukaemia via high
throughput screening of our in-house NPL and bio-
logical testing.
Jac-A, a characteristic constituent of H. japonicum,
was firstly reported by Kyoko Ishiguro et al. and charac-
terized by its inhibitory effect on PAF-induced
hypotension [17]. In this work, Jac-A was identified as
a new inhibitor of Bcl-2 proteins. We found that Jac-A
can compete for binding to BH3 domain of Bcl-2
Figure 6 Therapeutic study of Jac-A in the K562-bearing mice (n = 10/group). (A) Tumour volume plot of K562-bearing mice treated with
vehicle or Jac-A at 2, 10, or 50 mg/kg by oral gavage for 21 days. The tumours were measured twice per week. The data are represented as
the mean ± SEM. Tumour growth was inhibited significantly after treatment with Jac-A compared with the control group. *, P < 0.05; †, P < 0.01;
‡, P < 0.001 compared with the control group. (B) Selected nude mice models of different groups treated with Jac-A or vehicle at day 14 after
therapy. (C) Sizes of selected tumours harvested from dead nude mice bearing K562 cells from different groups treated with the vehicle or Jac-A.
(D) Kaplan-Meier survival plot of the K562-bearing nude mice. The survival of the K562-bearing nude mice was prolonged in the Jac-A treated
groups compared with control group. (E) Body weight plot of the K562-bearing nude mice. The data are represented as the mean ± SEM.
*, P < 0.05; †, P < 0.01; ‡, P < 0.001 compared with the control group.
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binding experiments. This result was confirmed by the
co-immunoprecipitation experiment whose results
showed Jac-A can inhibit the heterodimerization be-
tween antiapoptotic proteins (Bcl-xL, Bcl-2, and Mcl-1)
with pro-apoptotic proteins (Bax and Bak) in K562
cells. Moreover, Jac-A showed potent activity in indu-
cing the apoptosis of K562 cells. Simultaneously, we
found that Jac-A can promote the release of cyto-
chrome c into cytosol and trigger the activation of
downstream protein containing caspase-9, caspase-3,
and PARP. Additionally, we confirmed that Jac-A-
induced apoptosis in K562 cells is partly caspase-
dependent based on a broad-spectrum caspase inhibitorZ-VAD-FMK. In the in vivo test, Jac-A also showed a
dose-dependentlty inhibition for human K562 cell growth
in xenograph tumor mice with low toxicity.Conclusions
In summary, we identified the Jac-A, a characteristic
component of H. japonicum, induces apoptosis in K562
cells by inhibiting the heterodimerization of Bcl-xL /Bcl-2
with Bak, and Mcl-1 with Bax. Together with anticancer
activity in vivo, these works not only discovered a new lead
compound for cancer therapy with low toxicity, but also
provided evidence for using H. japonicum as an anti-
cancer herb.
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Additional file 1: Figure S1. (−)-Gossypol caused K562 cells apoptosis.
106 of K562 cells treated with 5 and 10 μM of (−)-Gossypol for 48 h. Cells
were then stained with Annexin V-FITC and propidium iodide, and
analysed using flow cytometry. Cells were treated with no Jac-A (A), 0.5%
DMSO (B), or 5 and 10 μM (−)-Gossypol (C and D).The results are one
representative of three independent experiments. Figure S2. Jac-A
caused HL-60 cells apoptosis. 106 of HL-60 cells treated with 10 μM of
Jac-A for 48 h. Cells were then stained with Annexin V-FITC and propidium
iodide, and analysed using flow cytometry. Cells were treated with no Jac-A
(A), 0.5% DMSO (B), or 10 μM Jac-A (C). The results are one representative of
three independent experiments. Figure S3. Jac-A caused THP-1 cells
apoptosis. 106 of THP-1 cells treated with 10 μM of Jac-A for 48 h. Cells
were then stained with Annexin V-FITC and propidium iodide, and
analysed using flow cytometry. Cells were treated with no Jac-A (A),
0.5% DMSO (B), or 10 μM Jac-A (C). The results are one representative of
three independent experiments. Figure S4. Jac-A caused LOVO cells
apoptosis. 106 of LOVO cells treated with 10 μM of Jac-A for 48 h. Cells
were then stained with Annexin V-FITC and propidium iodide, and
analysed using flow cytometry. Cells were treated with no Jac-A (A),
0.5% DMSO (B), or 10 μM Jac-A (C). The results are one representative
of three independent experiments.
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